HIV drug B/F/TAF tested in pregnancy for safety and virus control
NCT ID NCT07666386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety and effectiveness of the HIV medication B/F/TAF in pregnant women who have had their virus under control for at least six months. About 50 women in their first trimester will continue taking the drug through pregnancy and 12 weeks after birth. Researchers will track viral levels, side effects, and health outcomes for both mothers and babies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF)
What this could lead to
If successful, this study could provide real-world evidence that B/F/TAF is a safe and effective option for pregnant women with HIV, helping to maintain viral suppression during pregnancy.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to all pregnant women. It does not test a new treatment, and there is always a risk of side effects or loss of viral control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China